Zeda Zhang
Overview
Explore the profile of Zeda Zhang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
1173
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Mao N, Gao D, Hu W, Gadal S, Hieronymus H, Wang S, et al.
Cancer Res
. 2020 Feb;
80(7):1428-1437.
PMID: 32015092
Genomic rearrangements leading to the aberrant expression of ERG are the most common early events in prostate cancer and are significantly enriched for the concomitant loss of PTEN. Genetically engineered...
12.
Adams E, Karthaus W, Hoover E, Liu D, Gruet A, Zhang Z, et al.
Nature
. 2019 Jun;
571(7765):408-412.
PMID: 31243370
Mutations in the transcription factor FOXA1 define a unique subset of prostate cancers but the functional consequences of these mutations and whether they confer gain or loss of function is...
13.
Bose R, Karthaus W, Armenia J, Abida W, Iaquinta P, Zhang Z, et al.
Nature
. 2017 Jun;
546(7660):671-675.
PMID: 28614298
Half of all prostate cancers are caused by the TMPRSS2-ERG gene-fusion, which enables androgens to drive expression of the normally silent E26 transformation-specific (ETS) transcription factor ERG in prostate cells....
14.
Mu P, Zhang Z, Benelli M, Karthaus W, Hoover E, Chen C, et al.
Science
. 2017 Jan;
355(6320):84-88.
PMID: 28059768
Some cancers evade targeted therapies through a mechanism known as lineage plasticity, whereby tumor cells acquire phenotypic characteristics of a cell lineage whose survival no longer depends on the drug...
15.
Gao D, Zhan Y, Di W, Moore A, Sher J, Guan Y, et al.
PLoS One
. 2016 Aug;
11(8):e0161084.
PMID: 27536883
Fusion between TMPRSS2 and ERG, placing ERG under the control of the TMPRSS2 promoter, is the most frequent genetic alteration in prostate cancer, present in 40-50% of cases. The fusion...